Drugs.com - Pharma Industry News

Long-Term Gantenerumab May Slow Decline in Dominantly Inherited Alzheimer Disease

TUESDAY, March 25, 2025 -- For individuals with dominantly inherited Alzheimer disease (DIAD), long-term treatment with gantenerumab, an anti-amyloid beta antibody, may delay clinical decline, according to a study published in the April issue of The...

Mar 25, 2025 - 19:04
 0
Long-Term Gantenerumab May Slow Decline in Dominantly Inherited Alzheimer Disease
TUESDAY, March 25, 2025 -- For individuals with dominantly inherited Alzheimer disease (DIAD), long-term treatment with gantenerumab, an anti-amyloid beta antibody, may delay clinical decline, according to a study published in the April issue of The...
Read More

Tags:

Previous Article

Six Months of Breastfeeding Tied to Lower Odds of Developmental Delays

Next Article

High-Riding Patella Seen in ACL Reconstruction, Uninjured Contralateral Knees

Related Posts

Long-Term NSAID Use Linked to Reduced Dementia Risk

Long-Term NSAID Use Linked to Reduced Dementia Risk

Mar 6, 2025  0

Bleeding Risks for Oral Anticoagulants and Aspirin Mostly Similar

Bleeding Risks for Oral Anticoagulants and Aspirin Most...

Feb 11, 2025  0

Music-Based Interventions May Help Short-Term Depression, Behavior With Dementia

Music-Based Interventions May Help Short-Term Depressio...

Mar 11, 2025  0